Oruka Therapeutics Inc. (ORKA)
9.94
-0.21 (-2.07%)
At close: Mar 03, 2025, 3:59 PM
9.91
-0.25%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 9.39 |
| Market Cap | 347.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11.89 |
| Volume | 177,261 |
| Avg. Volume (20D) | 329,467 |
| Open | 10.59 |
| Previous Close | 10.15 |
| Day's Range | 9.80 - 10.38 |
| 52-Week Range | 9.53 - 53.88 |
| Beta | 0.62 |
About ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....
Industry Miscellaneous Commercial Services
Sector Industrials
IPO Date n/a
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol ORKA
Website http://www.orukatx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ORKA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 342.88% from the latest price.
Buy 87.50%
Hold 0.00%
Sell 0.00%
3 months ago
-6.43%
Oruka Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
6 months ago
+9.76%
Oruka Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $40 price target.